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Introduction: Overactive bladder (OAB) is a prevalent and persistent condition that is often 
under-diagnosed and under-treated, and which frequently requires tailored treatment for 
  successful management.
Methods: This consensus opinion-based review summarizes the discussions of a group of 
experts in the field of OAB that were assembled to evaluate the importance of correct diagnosis 
and appropriate pharmacotherapy in patients with OAB.
Results: A thorough diagnostic process is crucial for allowing exclusion of underlying medical 
issues and differentiation from genitourinary conditions other than OAB. In addition, selecting 
the most appropriate pharmacotherapy needs to be carefully considered in the context of each 
patient with OAB. In general, patients with OAB tend to be older with various comorbidities 
and often receiving multiple concomitant medications. Treatment decisions should take into 
consideration the differing potential for antimuscarinic medications to alter cognitive and car-
diovascular functions, both of which may be compromised in this patient population.
Conclusion: Tailoring treatment to individual patients by comprehensive patient assessment 
may lead to more effective management of patients with OAB, especially those receiving 
polypharmacy for comorbidities.
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Introduction
This short communication is a consensus opinion-based review highlighting the dis-
cussions of an advisory board of renowned experts in the field of overactive bladder 
(OAB). These professionals, who are all specialists in urogynecology or obstetrics 
and gynecology, were assembled to provide their perspectives on the importance 
of correct diagnosis and effective, appropriate treatment of patients with OAB. The 
remit of the advisory board was to discuss factors affecting diagnosis and successful 
pharmacotherapy of OAB with antimuscarinic agents. The participants who provided 
valuable input into the discussions and gave approval for this article are recognized 
in the acknowledgments.
OAB defined
OAB comprises a group of symptoms (ie, urinary urgency usually accompanied by 
increased frequency of micturition and nocturia with or without urgency incontinence), 
in the absence of urinary tract infection or other obvious pathology.1 This condition 
is highly prevalent, affecting approximately 12% of adults in Europe and Canada.2 
Prevalence increases with advancing age and is similar for men and women,   particularly Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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in the population $60 years of age.2 OAB can be a life-long, 
persistent (often lasting for at least 10 years), and progressive 
(from OAB without incontinence to OAB with incontinence) 
condition.3,4 Furthermore, OAB has a significant detrimental 
impact on patients’ quality of life, which is often greater than 
that resulting from other chronic diseases such as diabetes.5 It 
is therefore crucial that treatment strategies take into account 
that patients often require effective and well tolerated therapy 
for prolonged periods.
OAB: potential barriers  
to initial diagnosis
Recent publications have focused on the fact that OAB is 
undertreated, revealing that up to 76% of diagnosed patients 
remain untreated,6,7 but correct diagnosis is essential to ensure 
appropriate management of patients with urinary symptoms. 
Diagnosis may be hampered by patients failing to discuss 
their OAB symptoms, perhaps through embarrassment or the 
misconception that this condition is a normal part of aging 
and cannot be treated.5 Although physicians rely on patients’ 
complaints to trigger action, primary care physicians may 
not ask their patients about OAB symptoms,8 possibly due 
to time constraints, or lack of knowledge or awareness of 
available effective treatments. To overcome these barriers, 
questions on incontinence and bladder habits should ideally 
be included in the primary care physicians’ list of standard 
screening questions for all adult patients.8
Patient assessment
As the pathophysiology of OAB is not fully understood, the 
syndrome is a diagnosis of exclusion. Therefore, a holistic 
approach to patient assessment should be employed,5 includ-
ing appraisal of a patient’s genitourinary history as well as 
diagnostic tools and physical examination.
When a patient presents with symptoms that are potentially 
indicative of OAB, it is important to rule out other conditions 
that produce urological symptoms, such as bladder cancer, 
urinary tract infection, urethral inflammation, interstitial cys-
titis or simply urogenital atrophy, before initiating treatment. 
Initial assessments should focus on patients’   symptoms, but 
physical examination and diagnostic procedures should also be 
performed. Physical examination including pelvic examination 
(particularly in post-menopausal women) will exclude uro-
genital atrophy and pelvic organ prolapse. Indeed, it has been 
estimated that 23%–88% of patients with pelvic organ prolapse 
have varying combinations of urgency, urgency incontinence, 
frequency and/or nocturia.9 Urinalysis should determine 
if urinary tract infection (UTI) or urethral inflammation is 
present. UTI is the most common cause of bothersome urinary 
symptoms in women of all ages and treatable with antibiotics, 
however, symptoms of OAB will persist even after success-
ful treatment. In addition, routine measuring of post-void 
residual (PVR) volumes following micturition is often useful 
for determining urinary retention issues, especially in patients 
with bladder and prolapse symptoms, elderly patients with 
voiding symptoms and/or recurrent urinary tract infections, 
patients with neurogenic bladder and voiding dysfunction, 
and those patients with symptoms suggestive of decreased 
detrusor contractility or bladder outlet obstruction.5 The vol-
ume of residual urine can be measured either directly with a 
catheter inserted into the bladder (in-and-out catheterization), 
or indirectly with an ultrasound scan.
In the majority of patients with symptoms indicative 
of OAB, urodynamic assessment (beyond PVR testing) is 
not usually required. However, in some cases urodynamic 
assessment will provide a definitive diagnosis.5 Cystometry 
and measurement of PVR will exclude detrusor hyperactivity 
with impaired contractility (DHIC) during voiding, as 70% 
of women over the age of 70 years with symptoms of OAB 
may have DHIC.10 Furthermore, in cases where treatment 
with antibiotics and antimuscarinics has failed to improve 
symptoms, cytology and cystoscopy would exclude bladder 
neoplasias and interstitial cystitis. Indeed, urodynamic stud-
ies are indicated for specific patient types: OAB refractory 
to pharmacotherapy based on symptoms; women with sus-
pected outlet obstruction; and OAB associated with concur-
rent neurological disease. However, the role of urodynamic 
assessment in OAB diagnosis is not clearly defined currently. 
Evidence has shown that urodynamic diagnosis of detru-
sor overactivity and symptomatic diagnosis of OAB only 
  co-existed in 54% of patients classified as having OAB.11
Bladder diaries or frequency/volume charts are very helpful 
but often underutilized tools in the diagnosis of OAB that allow 
physicians to review patients’ accurate record of micturition 
frequency, number of incontinence episodes and urinary leak-
age, as well as fluid intake. There are various different formats 
for the bladder diary but all assess similar parameters. Bladder 
diaries can be used to evaluate stress and urgency associated 
with incontinence (OAB-related   incontinence), thereby help-
ing physicians to distinguish between stress incontinence and 
urgency   incontinence. Differentiating between these two condi-
tions is important for selecting appropriate management strate-
gies. Stress incontinence should be managed with pelvic floor 
exercises for at least 3–6 months before referral for surgery. 
  Recommended first-line therapy for OAB includes   behavioral 
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bladder retraining, and pelvic floor exercises) with or without 
pharmacotherapy. Many patients with OAB start on anticho-
linergic therapy with bladder training, then after 1 month are 
reviewed and advised on next steps. Continual reassessment 
of the patient may aid symptom management, especially with 
pharmacotherapy.
Determination of a patient’s medical history is not only 
vital for assessing genitourinary history but also comor-
bidities, which may affect treatment options. Looking at 
full patient profiles rather than just their symptoms could 
aid treatment choice and, importantly, allow treatment to be 
individualized to each patient’s needs.
Comorbidities and antimuscarinic 
therapy
Antimuscarinic agents are the mainstay of pharmacotherapy 
for OAB. It is widely agreed that antimuscarinic agents have 
similar efficacy but different tolerability and safety profiles. 
One of the main differences is the varying potential of 
antimuscarinics to alter cognitive and cardiac functions.12,13 
These potential effects are of particular concern for OAB 
patients, who tend to be older and are often receiving 
concomitant medication for a variety of other conditions, 
including those relating to cognitive and cardiac function 
(Figure 1).14–16 Therefore, the patient’s concomitant medi-
cations and comorbidities should be carefully considered 
when selecting antimuscarinic therapy for the management 
of OAB, which highlights the need for tailored therapy.
Increasing age has been associated with reduced cognitive 
function and greater permeability of the blood–  brain barrier, 
which can leave patients more vulnerable to the central ner-
vous system effects of drugs with anticholinergic   properties.12 
To date, darifenacin has the most clinical evidence (three 
randomized, double-blind, placebo-controlled studies in 
healthy participants, n = 302) for a lack of effect on cogni-
tive function. In contrast, oxybutynin has been associated 
with a decline in cognitive function, especially memory 
loss, compared with placebo, darifenacin and tolterodine.12 
Memory loss is of particular concern in older patients who 
may be receiving concomitant medication. A recent case 
study reported that memory loss secondary to administra-
tion of oxybutynin in a 66-year-old female with OAB led to 
non-adherence to medication regimens.17
Specific data on cognitive function are limited for other 
antimuscarinic agents, although small clinical studies 
with tolterodine (n = 22 healthy participants), solifenacin 
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Figure 1 The prevalence of overactive bladder (OAB), taking prescription medicines and comorbidities all increase with age.14–16Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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(n = 12 healthy participants) and trospium (n = 12 patients 
with OAB) have compared these agents favorably with both 
placebo and/or oxybutynin.12,18,19
Impairment of cognitive function may also be increased 
as a result of ‘hidden’ anticholinergic effects of concomitant 
medications administered for a variety of comorbid conditions 
unrelated to OAB. These medications add to the total anticho-
linergic burden on the patient and may cause non-degenerative 
mild cognitive impairment.20 Commonly prescribed drugs that 
have anticholinergic effects include: cimetidine, predniso-
lone, digoxin, furosemide, isosorbide dinitrate, warfarin, and 
codeine. Therefore, awareness of concomitant comorbidities 
and associated medications is of particular importance and 
careful management of patients’ medication is required to 
avoid prescribing agents with potential drug–drug interac-
tions related to their mechanisms of action and/or side-effect 
profiles. For example, the administration of anticholinergics 
for OAB therapy may potentially occur at the same time 
as cholinesterase inhibitors (eg, donepezil, rivastigmine), 
which are typically used to improve memory and cognition 
in Alzheimer’s disease. In addition, medications often used in 
persons with diabetes, such as thiazolidinediones for glucose 
control and gabapentin for neuropathic pain, can lead to noc-
turia; and the use of anticholinergic agents in the treatment of 
Parkinson’s disease can impair bladder emptying.21
In addition to the decline in cognitive function, advancing 
age is associated with increasing prevalence of cardiovascular 
(CV) disease.16 Moreover, CV disease occurs more frequently 
in patients with OAB than those without OAB.22 In a recent 
US database analysis of .6000 patients with OAB, 39% had 
some type of CV comorbidity at the time of OAB diagnosis 
compared with 21% of age-matched non-OAB patients 
(P , 0.0001).22 Hypertension (21%), diabetes (8%), CV 
symptoms (6%), and ischemic heart disease (6%) were the 
most common CV conditions.22
Antimuscarinics have the potential to increase CV risk 
through prolongation of the QT interval, which may lead 
to potentially fatal cardiac tachyarrhythmia or torsade de 
pointes,23 and increased heart rate.13,24 Faster resting heart 
rate, even by single digit increases, is associated with an 
increased risk of CV events and death in patients with and 
without CV disease (Figure 2).25 In an observational longitu-
dinal study, an increase in heart rate of only 5 bpm was asso-
ciated with a 16%–17% increase in mortality (P = 0.03).25 
Added to this, analysis of a separate US database indicated 
that almost 40% of patients with OAB had an elevated heart 
rate of $80 bpm before receiving antimuscarinic treatment.22 
Hence, any further increases in heart rate resulting from 
antimuscarinic treatment may add to the CV risk. Selected 
antimuscarinic agents, such as tolterodine, have been 
associated with increased heart rate (between 2–12 bpm) 
compared with placebo in clinical studies enrolling healthy 
volunteers.13,24 In contrast, darifenacin did not increase heart 
rate from baseline compared with placebo or tolterodine.13,24 
Although the magnitude of heart rate effects observed in 
these studies13,24 may not be of consequence in healthy 
volunteers, the same changes may have a greater impact in 
patients with an established higher risk for CV events and 
CV   comorbidities, such as patients with OAB.
These data demonstrate that patient comorbidities should 
be considered carefully during the treatment of OAB. 
  However, as there are no guidelines for the treatment of 
patients with OAB and comorbidities, the medication needs 
of each patient should be individually assessed and resulting 
treatment tailored appropriately.
Conclusion
The expert panel noted that ideally more patients should be 
treated successfully in the primary care setting, which would 
leave only those patients requiring specialist help being referred 
as and when appropriate. However, the main findings from the 
advisory board centered on the need for more comprehensive 
assessment of patients, which should assist in the correct 
diagnosis of OAB, and suitable   pharmacotherapy for patients 
with OAB and comorbidities. In particular, increased aware-
ness of the differences between antimuscarinic agents should 
allow for appropriate treatment of patients with OAB and 
comorbidities, who may be receiving concomitant   medications. 
Figure  2  increased  heart  rate  is  associated  with  increased  cardiovascular 
mortality.
Notes: aP , 0.05; bP , 0.01 for increased risk of cardiovascular mortality versus 
risk ratio of 1.0. Relative hazards were calculated by Cox proportional hazard model 
and adjusted for variables. Adapted with permission from Macmillan Publishers Ltd: 
American Journal of Hypertension, Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic 
value of home heart rate for cardiovascular mortality in the general population: the 
Ohasama study. Am J Hypertens. 2004;17(11 Pt 1):1005–1010.25, Copyright 2004.
Abbreviation: bpm, beats per minute.
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  Antimuscarinics have differing potential to negatively impact 
on patients’ CV and CNS function, which could result in a 
reduction of quality of life, hence patients may benefit from 
treatment tailored towards their individual needs.
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